11.21.16
Mayne Pharma has launched temozolomide capsules in the U.S. in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg doses. The generic version of branded Temodar, temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiform concomitantly with radiotherapy and then as maintenance treatment.
Temozolomide capsules had U.S. sales of approximately $150 million for the 12 months ending September 30, 2016, according to IMS Health.
Mayne Pharma will distribute the drug on behalf of its partner, IDT Australia, which developed the product and is manufacturing the product.
“Since entering the U.S. in 2012, Mayne Pharma has aggressively expanded its product portfolio, through internal product development, strategic acquisition, In-Licensing and working collaboratively with partners like IDT,” said Stefan Cross, president, Mayne Pharma USA. “Mayne Pharma now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting U.S. markets with IMS Health sales greater than $6 billion.”
Temozolomide capsules had U.S. sales of approximately $150 million for the 12 months ending September 30, 2016, according to IMS Health.
Mayne Pharma will distribute the drug on behalf of its partner, IDT Australia, which developed the product and is manufacturing the product.
“Since entering the U.S. in 2012, Mayne Pharma has aggressively expanded its product portfolio, through internal product development, strategic acquisition, In-Licensing and working collaboratively with partners like IDT,” said Stefan Cross, president, Mayne Pharma USA. “Mayne Pharma now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting U.S. markets with IMS Health sales greater than $6 billion.”
